Significant progress in the production of Dicot's drug candidate

The production is a semis-synthesis, where plant material is extracted whereafter natural molecules are purified from the extract. These are further synthesized to the drug substance included in the future drug product Libiguin®. Dicot has been working on streamlining and scaling up the manufacturing process to enable the production of sufficient amounts of drug substance for the activities now being undertaken in the pre-clinical program as well as for the upcoming phase 1 studies.  The very positive production result means that the availability of drug substance is secured far into the clinical phase.

"It is a very important step in the development of our drug candidate that has now been achieved together with Anthem Biosciences in India. Increasing the efficiency of production in this way means that we produce much larger quantities and that the cost per gram produced drug substance falls significantly. "says Göran Beijer, CEO of Dicot AB.